MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $60.75 (108.62% upside)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetActions
12/17/2015Goldman SachsInitiated CoverageBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/20/2015Cowen and CompanyReiterated RatingBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2015Morgan StanleyBoost Price TargetOverweight$61.00 -> $62.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/5/2015Cowen and CompanyReiterated RatingBuy$45.00 -> $65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2015Credit SuisseInitiated CoverageOutperform$51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015Credit SuisseBoost Price Target$51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/8/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha